Please assess the completion status of the following clinical trial:

Trial Title: Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients;~* Age \> 18 years;~* Type 2 diabetes patients on low or high sodium diet and stable RAS inhibitor therapy with the following conditions:~Urinary albumin excretion (UAE) rate \>300mg/24 hours (200 mcg/min); Serum creatinine \<2 mg/dL, PTH ≥ 20 mEq/L and \<110 mEq/L; Calcium and phosphorus levels \< 9.5 mg/dl and \< 5mg/dl, respectively; Controlled BP (systolic/diastolic \<140/90 mmHg) while on stable RAS inhibitor therapy;~- Written informed consent.~Exclusion Criteria:~* Previous Vitamin D or Vitamin D analogs therapy (within 3 months prior to the study entry);~* Evidence of toxicity to Vitamin D;~* History of kidney stones;~* Poorly controlled Diabetes: Hb1Ac \> 12%;~* Therapy with calcitonin, bisphosphonates, cinacalcet, glucocorticoids, immunosuppressive drugs or other drug that may affect calcium or bone metabolism;~* Cancer and any severe systemic disease or clinical condition that may jeopardize data interpretation or completion of the study;~* Any clinically relevant conditions that might affect study participation and/or study results;~* Any contraindication to be exposed to Paricalcitol;~* Pregnancy or lactating;~* Women of childbearing potential without following a scientifically accepted form of contraception;~* Legal incapacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Paricalcitol (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).